Testing Lutathera for meningioma that keeps growing after radiation
Official title: Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests a drug called Lutathera in people whose meningioma kept growing after radiation.
Read our full plain-language summary
What the trial team says
This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation therapy. Lutathera is a radioactive drug administered in the vein that is designed to target and kill tumor cells. The goal of this study is to determine whether this drug is safe and effective in treating meningiomas that progress after radiation treatment. WHO Grade I and Cohort WHO II/III cohorts will be evaluated.
Key facts
- Registry number
- NCT04082520
- Stage of testing
- Phase 2
- Conditions studied
- Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma, Unresectable Meningioma
Where it is running
This trial lists 1 site.
-
Minnesota
- Mayo Clinic in Rochester (Rochester)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.